NCT06552741 Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
| NCT ID | NCT06552741 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute on Drug Abuse (NIDA) |
| Condition | Substance Use Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2024-09-04 |
| Primary Completion | 2045-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2024-09-04 with a primary completion date of 2045-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: People who will participate in research studies need to undergo proper screening, evaluation, and assessment (SEA). SEA helps keep those who participate in studies safe. It also helps ensure accurate study results. The National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) wants to screen people with alcohol and/or substance use disorders (ASUD) as well as people without ASUD for ongoing studies at NIDA in Baltimore, MD Objective: To screen people with or without ASUD for ongoing studies at NIDA. The ultimate goals are to learn why some people (1) use drugs; (2) stop using drugs; (3) use drugs but do not get addicted; and (4) never use drugs snd to develop ASUD treatments. Eligibility: People aged 18 years and older. They may (1) currently use nicotine, alcohol, opioids, cocaine, or other drugs; (2) no longer use them; or (3) have never used them. Design: Participants will have 1 screening visit that could last up to 8 hours. The visit may be split over more than 1 day. The duration of the screening may vary for each individual based on which studies they are interested in and screened for. The tests they undergo may vary and may include the following: * Physical exam. * Blood, saliva, and urine tests. * Breath samples that test for alcohol and carbon monoxide. * Test of heart function. * Smell test that measures sense of smell. * Tests of memory, attention, and thinking. * Mental health evaluation. * Mock magnetic resonance imaging (MRI) scan. * Questionnaires about alcohol and other drug use, mental health, medical history, and life in general.
Eligibility Criteria
* INCLUSION CRITERIA: This protocol is seeking individuals with current or past SUDs and/or AUD, as well as those who have never had an SUD or AUD. These individuals also may or may not be in treatment for their AUD/SUDs. To be eligible to participate in this study, an individual must meet the following criteria: * Age 18-99 years old. * Proficient ability to read, write, and understand English. * Stated willingness to comply with all screening procedures and availability for the duration of the screening period * Ability of subject to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: Individuals who lack capacity to consent to research participation to this protocol as determined by the Evaluation to Sign Consent (ESC).
Contact & Investigator
Lorenzo Leggio, M.D.
PRINCIPAL INVESTIGATOR
National Institute on Drug Abuse (NIDA)
Frequently Asked Questions
Who can join the NCT06552741 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Substance Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06552741 currently recruiting?
Yes, NCT06552741 is actively recruiting participants. Contact the research team at pfistners@nida.nih.gov for enrollment information.
Where is the NCT06552741 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06552741 clinical trial?
NCT06552741 is sponsored by National Institute on Drug Abuse (NIDA). The principal investigator is Lorenzo Leggio, M.D. at National Institute on Drug Abuse (NIDA). The trial plans to enroll 10,000 participants.